In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tmunity's Series A brings in $100mm; $35mm added

Executive Summary

Tmunity Therapeutics Inc. (T-cell therapies for cancer, infectious diseases, and autoimmune conditions) raised $100mm through its Series A round. Seed investors University of Pennsylvania and Lilly Asia Ventures were joined by new investors Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences Inc., and Be The Match BioTherapies.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies